- Global Pharma News & Resources

Worldwide Allergic Conjunctivitis Industry to 2027 - by Countries, Disease Type, Pipeline Drugs and Company Analysis -

DUBLIN--(BUSINESS WIRE)--The "Allergic Conjunctivitis Market, Global Forecast Treated Patients By Countries, Disease Type, Pipeline Drugs, Company Analysis" report has been added to's offering.

According to this report the allergic conjunctivitis market was US$ 1.5 Billion in 2020 is expected to grow with a CAGR of 8.81% and reach US$ 2.7 Billion by 2027.

Allergic conjunctivitis is common ophthalmic disorder caused by reactions to allergens like pollen or mold spores, dust mites and animal fur. The eyeball has a membrane called conjunctiva which is receptive towards the irritation from allergens.

In July 2020, IACTA Pharmaceuticals & Zhaoke Ophthalmology Pharmaceuticals Ltd has signed an agreement to accelerate the development of drugs called IC265 and IC 270. Earlier they were develop to treat dry eye and later for allergic conjunctivitis.

There are many types of allergic conjunctivitis such as seasonal allergic conjunctivitis is caused by airborne mold spores, spring, late summer, or early fall and disappear during the winter month & perennial allergic conjunctivitis is caused by dust, mites, animal dander, and other non-seasonal allergens.

There has been significant increase allergic conjunctivitis due to increase in the use of chemicals and pollution caused by urbanization, industrialization and climate change. The increase in awareness of allergic conjunctivitis is associated its medical treatment & upcoming therapies such as Zerviate, ADX-102, PRT-2761, OTX-DP etc. is one of the factors driving the market.

The publisher has studied by region of North America followed by Europe and Asia-Pacific. The allergic conjunctivitis treatment market in Asia Pacific is expected to grow rapidly, due to having a large population base and increased demand of improved health facilities.

Company Covered

  • Santen Pharmaceutical
  • Alcon (Novartis)
  • Portola Pharmaceuticals
  • Ocular Therapeutix

Key Topics Covered:

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Dynamics

4.1 Growth Drivers

4.2 Challenges

5. Global Allergic Conjunctivitis Market and Patients Analysis

5.1 Market

5.2 Patient Numbers

5.3 Treated Patient Numbers

6. Share Analysis - Global Allergic Conjunctivitis

6.1 Country Market Share

6.2 Patients Population Share

6.3 Treated Patients Population Share

6.4 By Disease Type Share

7. India - Allergic Conjunctivitis Analysis

7.1 Patient Numbers

7.2 Treated Patient Numbers

7.3 Market

8. China - Allergic Conjunctivitis Analysis

8.1 Patient Numbers

8.2 Treated Patient Numbers

8.3 Market

9. Japan - Allergic Conjunctivitis Analysis

9.1 Patient Numbers

9.2 Treated Patient Numbers

9.3 Market

10. United States - Allergic Conjunctivitis Analysis

10.1 Patient Numbers

10.2 Treated Patient Numbers

10.3 Market

11. United Kingdom - Allergic Conjunctivitis Analysis

11.1 Patient Number

11.2 Treated Patient Numbers

11.3 Market

12. France - Allergic Conjunctivitis Analysis

12.1 Patient Numbers

12.2 Treated Patient Numbers

12.3 Market

13. Germany - Allergic Conjunctivitis Analysis

13.1 Patient Numbers

13.2 Treated Patient Numbers

13.3 Market

14. Italy - Allergic Conjunctivitis Analysis

14.1 Patient Numbers

14.2 Treated Patient Numbers

14.3 Market

15. Spain - Allergic Conjunctivitis Analysis

15.1 Patient Numbers

15.2 Treated Patient Numbers

15.3 Market

16. Disease Type - Global Allergic Conjunctivitis Market

16.1 Seasonal Allergic Conjunctivitis (SAC) & Perennial Allergic Conjunctivitis (PAC)

16.2 Vernal Keratoconjunctivitis (VKC)

16.3 Atopic Keratoconjunctivitis (AKC)

16.4 Giant Papillary Conjunctivitis (GPC)

17. Global Allergic Conjunctivitis Pipeline Drugs

17.1 Zerviate

17.2 OTX-DP (Dexamethasone Insert)

17.3 ADX-102

17.4 PRT2761

17.5 CVXL-0074

17.6 AK-002

17.7 Bertilimumab

17.8 Reproxalap

17.9 ST-266

17.10 SYL-116011

18. Company Analysis

18.1 Santen Pharmaceutical

18.1.1 Company Overview

18.1.2 Recent Developments

18.1.3 Financial Insight

18.2 Alcon Inc. (Novartis)

18.2.1 Company Overview

18.2.2 Recent Developments

18.2.3 Financial Insight

18.3 Portola Pharmaceuticals Inc.

18.3.1 Company Overview

18.3.2 Recent Developments

18.3.3 Financial Insight

18.4 Ocular Therapeutix Inc.

18.4.1 Company Overview

18.4.2 Recent Developments

18.4.3 Financial Insight

For more information about this report visit

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Editor Details

  • Company:
    • Businesswire
Last Updated: 09-Apr-2021